Feature

There is a chance that not only will stem cell therapy enter the mainstream, but that IFAs will be advising on it. As a pilot opens in the UK, Sue Wilkinson outlines the case.

The downgrading of protection's value post purchase is a prime factor in making it a grudge purchase, according to recent research. Jo Miller says better contact with customers is key to changing consumer attitudes.

Robin Hyndley looks at what the latest DWP proposals mean for employers and employees, and explores how insurers could provide appropriates in the current environment.

For such a well-known condition, MS is difficult to pin down, as Neil Hartigan explains.

Protection providers will soon be considering customer telematics. Phil Jeynes examines the consequences.

A change in pension tax rules could land some with group life policies with hefty bills. But, as Nick Rumble finds, there are solutions.

Pension reforms are driving the most prominent changes in group life. Fiona Murphy takes a look at market developments.

Annual statements would help advisers to sell more protection. Adam Higgs reveals how.

Munich Re research has found non‑disclosure to be a lot more common than previously thought. As Lee Lovett explains, stopping it is not easy.

One of the most exciting medical advancements in recent times is Nanomedicine, the development of microscopic particles with healing effects. Dr Ulrike Sucher offers a health insurer's perspective.